Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Paynova in conjunction with raising of capital and change in listing
Mandate

Vinge advises Paynova in conjunction with raising of capital and change in listing

June 07, 2022 Capital Markets and Public M&A

Vinge has advised Paynova AB, under change of name to Sileon AB, in connection with a fully subscribed rights issue valued at approximately SEK 70 million.  

In connection with the issue, Paynova has also made public their intention to implement a change of listing from NGM Regulated to Nasdaq First North Growth Market.

Vinge’s team consisted of, among others, Anders Strid, Edin Agic (project manager), Adrian Filipovic and Amelia Rihs.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026